| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Pgf; PGFL; PIGF; Placenta growth factor; Placental growth factor; vascular endothelial growth factor related protein; PlGF; PlGF2; SHGC 10760 |
| Entrez GeneID | 5228 |
| WB Predicted band size | Calculated MW: 25 kDa; Observed MW: 25 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human PLGF |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于PLGF抗体的3篇代表性文献示例(注：文献信息为模拟示例，仅供参考)：
1. **《Anti-PlGF antibodies inhibit tumor growth and metastasis through impaired angiogenesis》**
- 作者：R. Fischer et al.
- 摘要：研究证明抗PLGF单克隆抗体通过靶向肿瘤相关巨噬细胞(TAMs)抑制血管生成，显著减少小鼠模型中肿瘤生长和转移，且不影响正常血管功能。
2. **《Targeting placental growth factor (PlGF) in neovascular age-related macular degeneration》**
- 作者：L. Van de Veire et al.
- 摘要：临床试验表明，抗PLGF抗体联合抗VEGF疗法可增强对AMD患者脉络膜新生血管的抑制效果，减少视网膜渗漏，提示PLGF是抗血管生成治疗的潜在靶点。
3. **《PlGF blockade ameliorates inflammatory arthritis by suppressing angiogenesis and macrophage activation》**
- 作者：M. Odorisio et al.
- 摘要：实验发现，PLGF抗体通过抑制滑膜血管增生和巨噬细胞炎症反应，显著减轻类风湿性关节炎模型中的关节损伤和炎症，为自身免疫疾病治疗提供新策略。
4. **《Placental growth factor inhibition modulates tumor microenvironment and enhances chemotherapy efficacy》**
- 作者：J. Zhang et al.
- 摘要：研究表明，抗PLGF抗体通过重塑肿瘤微环境(如降低缺氧和免疫抑制细胞浸润)，增强化疗药物在结直肠癌模型中的抗肿瘤效果。
(注：以上文献信息为综合领域知识生成的示例，实际引用需查询具体数据库如PubMed获取真实文献。)
Placental Growth Factor (PLGF), a member of the vascular endothelial growth factor (VEGF) family, plays a critical role in pathological angiogenesis, inflammation, and tissue repair. Primarily expressed during placental development, PLGF is upregulated in various diseases, including cancer, ischemic disorders, and inflammatory conditions. Unlike VEGF-A, which is essential for physiological and pathological angiogenesis, PLGF specifically enhances pathological vessel growth by binding to VEGF receptor-1 (VEGFR-1) and amplifying pro-angiogenic signaling. This selective involvement makes PLGF a promising therapeutic target to minimize off-target effects on normal vasculature.
PLGF antibodies are designed to neutralize PLGF activity, disrupting its interaction with VEGFR-1 and downstream pathways. Preclinical studies show that anti-PLGF therapies inhibit tumor growth, metastasis, and aberrant angiogenesis in diseases like diabetic retinopathy and atherosclerosis, while sparing healthy blood vessels. Additionally, PLGF blockade may synergize with anti-VEGF therapies, overcoming resistance observed in some cancers. Despite encouraging results in animal models, clinical translation has faced challenges, with mixed outcomes in early-phase trials. Current research focuses on optimizing antibody specificity, delivery, and combination strategies. Overall, PLGF antibodies represent a targeted approach to modulate pathological angiogenesis with potential applications in oncology, ophthalmology, and cardiovascular diseases.
×
